Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
Abstract
While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following cell entry via the poliovirus receptor CD155, which is expressed on tumor and antigen-presenting cells. Preclinical studies show that oncolytic virus plus anti-PD-1 therapy leads to a greater antitumor response than either agent alone, warranting clinical investigation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2021
- Source ID
- 10.1136/jitc-2020-002203
Entities
People
- Andrea True Kelly
- April Ks Salama
- Carol Ann Wiggs
- Darell D. Bigner
- Georgia Beasley
- Karenia Landa
- Maria Angelica Selim
- Matthias Gromeier
- Norma E. Farrow
- Sin-ho Jung
- Smita K Nair
Organizations
- United States Department of Defense